(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Rosenberg reported long-term follow-up of the IMvigor210 Cohort 1. While cisplatin-based chemotherapy is the standard of care for first-line (1L) metastatic urothelial carcinoma (mUC), many patients are ineligible for treatment with cisplatin. Thus, Cohort 1 of the single-arm phase II IMvigor210 study evaluated the efficacy and safety of first-line atezolizumab (anti–PD-L1) in cisplatin-ineligible patients with mUC. These data formed the basis of the ongoing randomised phase III IMvigor130 study.